Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland

References

• Cancer.Net . Bladder cancer: introduction. www.cancer.net/cancer-types/bladder-cancer/introduction (Accessed: 21 April 2023 ).
   Google Scholar
• Public Health Scotland . Cancer statistics: bladder cancer. www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Bladder/ (Accessed: 21 April 2023 ).
   Google Scholar
• Davies F, Knott C, Kerr C, Lockhat M, Adedokun L. Utilising routine health data to establish a standing cohort of patients with metastatic bladder cancer: initial results and algorithm defining disease progression. europe2020-ispor.ipostersessions.com/Default.aspx?s=95-56-36-01-D0-00-15-AA-7F-9F-D4-84-35-78-E1-C7 (Accessed: 21 April 2023 ).
   Google Scholar
• Kearney M, Knott C, Lamy FX, Harnett J, Amin A, Verpillat P. Treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial cancer in England: results of a longitudinal observational cohort study. Value Health 23(Suppl. 2), S483 (abstract PCN341) (2020).
   Google Scholar
• Cheeseman S, Thompson M, Sopwith Wet al. Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre. Front. Oncol. 10, 167 (2020).
   PubMed Web of Science ®Google Scholar
• Powles T, Huddart RA, Elliott Tet al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J. Clin. Oncol. 35(1), 48–55 (2017).
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium . SMC2359: avelumab 20 mg/ml concentrate for solution for infusion (Bavencio®). www.scottishmedicines.org.uk/media/6187/avelumab-bavencio-final-july-2021-amended-050821-for-website.pdf (Accessed: 21 April 2023 ).
   Google Scholar
• European Medicines Agency . Bavencio (avelumab). www.ema.europa.eu/en/documents/product-information/bavencio-epar-product-information_en.pdf (Accessed 21: April 2023).
   Google Scholar
• Electronic Medicines Compendium . Bavencio 20 mg/ml concentrate for solution for infusion. www.medicines.org.uk/emc/product/8453/smpc#grefJ (Accessed: 21 April 2023 ).
   Google Scholar
• Powles T, Bellmunt J, Comperat Eet al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(3), 244–258 (2022).
   PubMed Web of Science ®Google Scholar
• Cathomas R, Lorch A, Bruins HMet al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81(1), 95–103 (2022).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . A study of avelumab in patients with locally advanced or metastatic urothelial cancer (JAVELIN Bladder 100). clinicaltrials.gov/ct2/show/NCT02603432 (Accessed: 21 April 2023 ).
   Google Scholar
• Powles T, Park SH, Voog Eet al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383(13), 1218–1230 (2020).
   PubMed Web of Science ®Google Scholar
• Grivas P, Kopyltsov E, Su PJet al. Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma. Eur. Urol. 83(4), 320–328 (2023).
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium . Avelumab (Bavencio). www.scottishmedicines.org.uk/medicines-advice/avelumab-bavencio-full-smc2359/ (Accessed: 21 April 2023 ).
   Google Scholar
• Scottish Medicines Consortium . Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®). www.scottishmedicines.org.uk/media/3134/atezolizumab-tecentriq-for-uc-final-feb-2018-for-website.pdf (Accessed: 21 April 2023 ).
   Google Scholar
• Scottish Medicines Consortium . Pembrolizumab 25mg/ml concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®). www.scottishmedicines.org.uk/media/3121/pembrolizumab_keytruda_final_jan_2018_for_website.pdf (Accessed: 21 April 2023 ).
   Google Scholar
• Scottish Medicines Consortium . Nivolumab 10mg/ml concentrate for solution for infusion (Opdivo®). www.scottishmedicines.org.uk/media/3114/nivolumab_opvido_final_dec_2017_for_website.pdf (Accessed: 21 April 2023 ).
   Google Scholar
• Scottish Medicines Consortium . Working with SMC: a guide for manufacturers. www.scottishmedicines.org.uk/media/7486/working-with-smc.pdf (Accessed: 21 April 2023 ).
   Google Scholar
• Office for National Statistics . National life tables: Scotland. www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesscotlandreferencetables (Accessed: 21 April 2023 ).
   Google Scholar
• Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. www.sheffield.ac.uk/media/34225/download?attachment (Accessed: 21 April 2023 ).
   Google Scholar
• Kelly K, Infante JR, Taylor MHet al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 124(9), 2010–2017 (2018).
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Orlova K, Grignani Get al. Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East. Int. J. Cancer 149(11), 1926–1934 (2021).
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen MF, Feng YSet al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15(5), 708–715 (2012).
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 13(5), 509–518 (2010).
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual. Life Outcomes 6, 84 (2008).
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making. 26(4), 410–420 (2006).
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Davies J, Leach Met al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual. Life Outcomes 8, 50 (2010).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence . Nivolumab with ipilimumab for untreated advanced renal cell carcinoma. http://www.nice.org.uk/guidance/ta581/history (Accessed: 21 April 2023 ).
   Google Scholar
• National Institute for Health and Care Excellence . Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy. www.nice.org.uk/guidance/ta378/history (Accessed: 21 April 2023 ).
   Google Scholar
• Gauci ML, Baroudjian B, Zeboulon Cet al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J. Hepatol. 69(2), 548–550 (2018).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence . BNF: British National Formulary – avelumab. bnf.nice.org.uk/medicinal-forms/avelumab.html (Accessed: 21 April 2023 ).
   Google Scholar
• National Institute for Health and Care Excellence . Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract. www.nice.org.uk/guidance/ta272/history (Accessed: 21 April 2023 ).
   Google Scholar
• National Institute for Health and Care Excellence . Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. www.nice.org.uk/guidance/ta492/history (Accessed: 21 April 2023 ).
   Google Scholar
• National Institute for Health and Care Excellence . Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. www.nice.org.uk/guidance/ta522/history (Accessed: 21 April 2023 ).
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2019. www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/ (Accessed: 21 April 2023 ).
   Google Scholar
• NHS England . 2018/19 National Cost Collection data publication. www.england.nhs.uk/publication/2018-19-national-cost-collection-data-publication/ (Accessed: 21 April 2023 ).
   Google Scholar
• Round J, Jones L, Morris S. Estimating the cost of caring for people with cancer at the end of life: a modelling study. Palliat. Med. 29(10), 899–907 (2015).
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence . BNF: British National Formulary. bnf.nice.org.uk/ (Accessed: 21 April 2023 ).
   Google Scholar
• National Institute for Health and Care Excellence . Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. www.nice.org.uk/guidance/ta788/history (Accessed: 21 April 2023 ).
   Google Scholar
• Peng Y, She Z, Peng Let al. Cost–effectiveness of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in the United States. Adv. Ther. 38(12), 5710–5720 (2021).
   PubMed Web of Science ®Google Scholar
• Karttunen E, Jaaskelainen S, Hervonen P, Chang J, Kearney M. Cost–effectiveness of avelumab as first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Finland. Poster presented at: ISPOR Europe 2021. Virtual, 30 November–3 December 2021. www.ispor.org/heor-resources/presentations-database/presentation/euro2021-3409/112147 (Accessed: 21 April 2023 ).
   Google Scholar
• Chang WC, Xiao Y, Lin AYet al. Cost–effectiveness analysis of avelumab plus best supportive care (BSC) vs BSC alone as a first-line (1L) maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan. Poster presented at: ISPOR Europe 2021. Virtual, 30 November–3 December 2021. www.ispor.org/heor-resources/presentations-database/presentation/euro2021-3407/112259 (Accessed: 21 April 2023 ).
   Google Scholar
• Powles T, Park SH, Caserta Cet al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J. Clin. Oncol. 41(19), 3486–3492 (2023).
   PubMed Web of Science ®Google Scholar